Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders
Fig 8
Concentration-response effects of compounds on the cAMP pathway via ADRB1.
Data are expressed as a percentage of maximum efficacy obtained with the full agonist isoproterenol. Values represents means ± S.E.M.s (1–2 experiments with n = 1–2).